HSV VACCINE FOR PATIENTS WITH GENITAL HERPES

在Prober博士的指导下，受试者已经参加了一项 评估一种疫苗的安全性、免疫原性和有效性的试验 单纯疱疹病毒2型(HSV-2)重组疫苗。这 这项试验是一项多中心、随机、安慰剂对照的评估 一种由埃默里维尔Chron Biocine公司开发的基于糖蛋白的疫苗， 加州。参赛者为单纯疱疹病毒2型感染者未感染的性伴 研究对象。疫苗效力的中期评估未能证明 而赞助商提前中止了这项研究。 尽管如此，常见和特定类型HSX的T细胞识别 在斯坦福大学注册的21名研究对象中测量了糖蛋白。 目前正在对这些回应进行分析，以便 与自然感染的人的反应相比。

Under the direction of Dr. Prober, subjects have been enrolled in a trial evaluating the safety, immunogenicity, and efficacy of a recombinant vaccine against herpes simplex virus type 2 (HSV-2). This trial is a multicentered, randomized, placebo-controlled evaluation of a glycoprotein based vaccine developed by Chiron Biocine, Emeryville, CA. Enrollees were HSV-2 uninfected sexual partners of HSV-2 infected subjects. Interim evaluation of vaccine efficacy failed to demonstrate benefit and the study was prematurely discontinued by the sponsor. Nonetheless, T-cell recognition of common and type-specific HSX glycoproteins was measured in the 21 study subjects enrolled at Stanford and these responses currently are being analyzed so that they can be compared with the resposes of naturally infected individuals.